Pharma BD Deal Intelligence
Shire's ~$4.0B all-stock acquisition of BioChem Pharma became a bust: within one quarter Shire booked $177M in impairments, the coveted anti-infectives pipeline never delivered a successor drug, and Shire divested the franchise by 2005 while the acquired 3TC/Epivir royalty stream simply declined toward generic entry.
Shire bought a royalty annuity, not the pipeline engine it paid for — and abandoned BioChem's anti-infectives business within 4 years
Full analysis, sources & comparables →The news sent Shire's shares tumbling 14 per cent... Shire's investors are concerned about share dilution. There are also some concerns about BioChem's track…
Creates one of the world's leading global specialty pharmaceutical companies... with opportunities for synergies, is expected to be accretive to Shire's…
BioChem shareholders received a 39.6% premium and shares rose 11% on news; Shire stock fell 16%, though analysts viewed the dip as 'a good buying opportunity.'
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
All-share merger announced Dec 2000; closed May 2001. ~$4B fully-diluted ($5.9B at announce). Canadian biotech; 3TC (lamivudine) royalties from GSK.
Shire bought a royalty annuity, not the pipeline engine it paid for — and abandoned BioChem's anti-infectives business within 4 years
Assessment window: 15yr post-close.
HIV/AIDS is a chronic viral infection in which HIV attacks CD4 T-cells, progressively undermining immune function. Around the time of the deal (2000-2001), antiretroviral therapy was transitioning to combination regimens (HAART) that suppressed viral load and converted HIV from a near-uniformly fatal disease into a manageable chronic condition for those with treatment access.
BioChem Pharma's flagship asset 3TC (lamivudine), marketed by GlaxoWellcome as Epivir, was a cornerstone of HIV combination therapy at the time of the Shire deal. By 2000-2001, 3TC anchored several front-line regimens including Combivir (3TC + AZT) and the newly launched Trizivir (3TC + AZT + abacavir). Competing nucleoside reverse transcriptase inhibitors (NRTIs) included Bristol-Myers Squibb's Zerit (stavudine) and Videx (didanosine), and Gilead's Viread (tenofovir, approved 2001). Non-NRTIs such as Sustiva (efavirenz, BMS) and Viramune (nevirapine, Boehringer Ingelheim) plus protease inhibitors like Crixivan (Merck) and Kaletra (Abbott) rounded out HAART backbones. BioChem did not directly market 3TC; its economics flowed through royalties from GlaxoWellcome (Epivir) and Shire's purchase was effectively a play on that royalty stream plus the hepatitis B franchise (Zeffix). The merger gave Shire a high-margin infectious-disease cash flow to complement its ADHD franchise (Adderall). Source: https://www.theglobeandmail.com/report-on-business/biochem-shire-in-59-billion-merger/article25713392/
Chronic hepatitis B (HBV) is a persistent liver infection that can progress to cirrhosis and hepatocellular carcinoma. In the early 2000s, oral antiviral options were limited and Zeffix (lamivudine for HBV) was one of the first nucleoside analog therapies indicated for chronic HBV.
Zeffix (lamivudine 100mg, lower dose than HIV's Epivir) was launched in key markets by GlaxoWellcome around 1998-1999 as one of the first oral nucleoside analogs for chronic HBV, competing with interferon alfa (Schering-Plough's Intron A and Roche's Roferon-A). At the time of the 2001 Shire-BioChem deal, the HBV oral antiviral market was nascent, and Zeffix held a strong first-mover position despite emerging concerns about resistance (YMDD mutations). Subsequent agents that would erode lamivudine's HBV share — Bristol-Myers Squibb's Baraclude (entecavir, 2005) and Gilead's Hepsera (adefovir, 2002) and Viread (tenofovir for HBV, 2008) — were not yet approved. The deal therefore captured Zeffix near peak share but also peak generic-resistance concern. Source: https://www.pharmaceuticalonline.com/doc/shire-pharmaceuticals-and-biochem-pharma-to-m-0001
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire Pharmaceuticals Group plc / BioChem Pharma Inc. (this deal) | 2001 | $4.0B | 33 |
| Shire Pharmaceuticals Group plc / Transkaryotic Therapies, Inc. (TKT) | 2005 | $1.6B | 72 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals